Transjugular intrahepatic portosystemic shunt (TIPS) is a shunt (tube) that sits between the portal vein, which carries blood from the intestine/spleen to the liver, and the hepatic vein, which carries blood from the liver to the vena cava, and the heart. TIPS are mostly done in patients with cirrhosis where scar tissue in the liver causes a partial blockage of blood flow from the portal vein through the liver to the hepatic vein.
The blockage in the liver increases the pressure in the portal vein, which is called portal hypertension. As a result of the increased pressure, portal blood flow bypasses the liver and is shunted into smaller veins that flow around the abdominal wall, stomach, and esophagus. Portal hypertension can also cause fluid from the liver to leak into the abdomen or right chest around the lung. The TIPS procedure is performed through a small incision on the right side of the neck through the internal jugular vein and the larger neck vein. Under radiographic guidance, a stent (metal tube/shunt) is placed from the hepatic vein to the portal vein.
According to the report, the global transjugular intrahepatic portosystemic shunt (TIPS) industry generated $93.4 million in 2021, and is estimated to reach $127.9 million by 2031, manifesting a CAGR of 3.2% from 2022 to 2031.
Download Free Sample Report
- CAGR: 3.2%
- Current Market Size: USD 127.9 Million
- Forecast Growing Region: APAC
- Largest Market: North America
- Projection Time: 2021 – 2031
- Base Year: 2021
Prime determinants of growth
Increase in prevalence of liver disease such as portal hypertension,
Budd-Chirai Syndrome, hepatorenal syndrome, and others, rise in risk of organ
failure, and development of new TIPS devices by large number of key players
drive the growth of the global transjugular intrahepatic portosystemic shunt
market. Moreover, rise in incidence of portal vein thrombosis and other liver
diseases among geriatric population and surge in demand for TIPS surgery due
to shortage of organ donors supplement the market growth. Also, rise in number of product approvals creates new opportunities in the coming years.
* The Covid-19 epidemic has had a negative impact on global growth
Transjugular intrahepatic portosystemic shunt (TIPS) market. Confinement
government-imposed restrictions and cancellation or postponement
of elective surgical procedures in hospitals has reduced the adoption of
surgical aids for TIPS surgery. * Due to lockdown restrictions and supply chain disruptions, there have been hurdles in manufacturing various types of devices such as stents and Accessories. However, these hurdles should be overcome as well Surgeries are expected to continue after the pandemic.
The hospitals segment to maintain its leadership position throughout the
Based on end user, the hospitals segment accounted for the largest market
share in 2021, contributing to around four-fifths of the global transjugular
intrahepatic portosystemic shunt market, and is estimated to maintain its
leadership position throughout the forecast period. This is due to rise in
number of hospital admissions and increase in demand for TIPS devices across
hospitals. However, the specialty clinics segment is expected to manifest the
largest CAGR of 3.9% from 2022 to 2031. This is due to surge in demand for
special treatment, increase in number of such facilities across developed and
emerging countries, and the presence of well-trained medical staff in
Customization Request: https://www.alliedmarketresearch.com/request-for-customization/31879
The stents segment to continue its leadership in terms of revenue throughout the forecast period
By device type, the stent segment contributed the highest market
share in 2021, which accounts for nearly three-fifths of the global transjugular
intrahepatic portosystemic shunts market and will maintain its leadership in the
terms of revenue for the entire forecast period. Also, this segment is
It is estimated to register the largest CAGR of 3.5% during the forecast period. This is attributed to the strong portfolio of stents with major market players,
increased research and development activities in the medical device sector and increased demand for TIPS devices. The report also analyzes the accessories segment.
The portal hypertension segment to continue its leadership status throughout the forecast period
According to the application, the portal hypertension segment ranked as the top market share in 2021, which accounts for more than four-fifths of the global transjugular intrahepatic portosystemic shunts market and will maintain its leadership in the terms of revenue for the entire forecast period. Also, this segment is
It is estimated to witness the highest CAGR of 3.3% from 2022 to 2031. This is
attributed to the increase in the number of portal hypertension cases and the increase of request for transjugular intrahepatic portosystemic shunt (TIPS) between
The report also examines segments that include Budd Chiari
Syndrome and others.
North America to continue its dominant share throughout the forecast period
Based on region, North America held the largest market share in 2021,
accounting for more than two-fifths of the global transjugular intrahepatic
portosystemic shunt market, and is projected to continue its dominant share
throughout the forecast period. This is attributed to rise in number of liver
surgeries, the presence of key players, development of the healthcare sector,
and offering of innovative TIPS devices in the region. However, Asia-Pacific
is estimated to witness at the fastest CAGR of 5.0% from 2022 to 2031, owing
to rise in use for lifetime support, development of healthcare infrastructure,
and expanding presence of major market players across the region. The research
also analyzes regions including Europe and LAMEA.
Leading Market Players
* Boston Scientific Corporation
* Becton, Dickinson and Company
* Angiodynamics, Inc.
* Cook Medical, Inc.
* Neuromedex GmbH
* W.L Gore & Associates, Inc.
Read More- https://www.alliedmarketresearch.com/press-release//transjugular-intrahepatic-portosystemic-shunt-tips-market.html